Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

Pharmacopeia Advances and Expands Internal Pipeline as DARA Program Enters

Phase 2 Clinical Development and New SARM Program is Added

PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP) today announced results for the quarter and nine months ended September 30, 2007, and highlighted several important developments in its therapeutic programs and corporate milestones achieved since the beginning of the quarter.

During the third quarter of 2007:

-- Pharmacopeia announced the initiation of a Phase 2a hypertension

clinical trial for PS433540, an unpartnered product candidate from its

DARA program, that is both an angiotensin receptor blocker (ARB) and an

endothelin receptor antagonist (ERA). The trial was initiated less

than one year after IND submission and approximately six months ahead

of schedule.

Also during the quarter, the company announced positive results from

multiple Phase 1 clinical studies for PS433540. These Phase 1 findings

included:

-- PS433540 demonstrated its ability to block the increase in blood

pressure induced by administration of angiotensin II (AII) to

healthy volunteers. Numerous similar studies with other agents that

block the renin-angiotensin system support that this result is a

strong indication that PS433540 can be expected to lower blood

pressure in hypertensive patients. This Phase 1 study showed that

all doses of PS433540, compared with placebo, produced a

statistically significant (p<0.01) inhibition of the expected AII-

induced increase in blood pressure. Additionally, the findings

showed that the 250 mg and 500 mg doses of PS433540 were at least as

effective in blocking the AII response as irbesartan, a leading

angiotensin receptor blocker that is approved for th
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3,  2015 About ... bio-artificial devices, which are implanted or integrated ... organs. These include artificial heart, kidney, pancreas, ... polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ... artificial organs. These organs are incorporated with ...
(Date:9/3/2015)... About dry eye syndrome Dry eye syndrome usually ... production or quick tear evaporation or deviation in tear ... deficient dry eye and evaporative dry eye. In aqueous ... enough tears, whereas meibomian gland dysfunction results in evaporative ... evaporation and maintain tear stability. The symptoms include pain, ...
(Date:9/3/2015)... Denmark , Sept. 3, 2015 /PRNewswire/ ... a clinical stage biotechnology company that applies ... unmet medical needs, today announced plans to ... 2015 Wells Fargo Healthcare Conference in BostonDate: ... EDTEvent: , Bank of America Merrill Lynch ...
Breaking Medicine Technology:Global Artificial Organ Market 2015-2019 2Global Dry Eye Syndrome Market 2015-2019 2Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
(Date:9/4/2015)... ... 2015 , ... With TransCel from Pixel Film Studios users can simulate celluloid ... With TransCel users have full control over camera position and angle within 3D space ... inner color, text, and more. With TransCel the possibilities are endless. , Users have ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... The Schmidt ... of Tanya De La Paz. , Schmidt National Law Group, a leading firm ... District of California against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for ...
(Date:9/4/2015)... , ... September 04, 2015 , ... IVF New England, ... a New Hampshire fertility "ManchVegas Happy Hour" in Manchester for women who wish to ... 2015 at XO on Elm restaurant and lounge, 827 Elm Street, Manchester, NH from ...
(Date:9/4/2015)... ... , ... After wearing the same uniforms for six seasons, the Sprayberry High ... to assist the team, the Jones Agency, a locally owned insurance firm that serves ... the new uniforms. , As is so often the case with high school and ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... out to benefit Core Compassion Project. Core Compassion Project is a non-profit ... program to reduce the side effects of cancer treatments and recover their mobility, ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2
... , , , ... BOSTON, Aug. 10 PAREXEL International Corporation (Nasdaq: ... Year ended June 30, 2009. The Company has determined the need ... described in greater detail below. These changes relate to (1) the ...
... ... advising sufferers of Seasonal Affective Disorder (SAD), a condition that usually affects people during the ... keep symptoms of SAD at bay. , ... Cambridge (PRWeb UK) August 10, 2009 -- Based on light measurements taken for ...
... N.J., Aug. 10 Pharmasset, Inc. (Nasdaq: VRUS ), ... novel drugs to treat viral infections, today reported financial results and ... , , Financial Results , ... June 30, 2009 compared to $0.5 million for the quarter ended ...
... TSX: COM, , , VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ ... a teleconference call and webcast will be held at 9:00am ... 2009 second quarter financial results. , To access the conference ... There will be a separate dial-in line for analysts on ...
... , , Increased caseloads, ... concerns , , WASHINGTON, Aug. 10 ... approximately 4,000 HIV-treating clinicians in the United States [out of a ... survey indicating that while supportive of ongoing health care reform efforts, ...
... 10 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: MR ), ... its selected unaudited,financial results for the second quarter and first half ... Second Quarter and First Half 2009, -- Second ... 9.9% over the second quarter of ...
Cached Medicine News:Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 2Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 3Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 4Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 5Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 6Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 7Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 8Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 9Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 10Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 11Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 12Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 13Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 14Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 15Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 16Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 17Health News:Lumie Reveals Light Levels Received In July Are As Low As A Winter's Day 2Health News:Lumie Reveals Light Levels Received In July Are As Low As A Winter's Day 3Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 2Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 3Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 4Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 5Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 6Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 7Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 8Health News:Cardiome to Hold Conference Call 2Health News:Cardiome to Hold Conference Call 3Health News:HIV-Treating Clinicians Support Health Care Reform, Express Caution 2Health News:HIV-Treating Clinicians Support Health Care Reform, Express Caution 3Health News:HIV-Treating Clinicians Support Health Care Reform, Express Caution 4Health News:HIV-Treating Clinicians Support Health Care Reform, Express Caution 5Health News:Mindray Announces Second Quarter 2009 Financial Results 2Health News:Mindray Announces Second Quarter 2009 Financial Results 3Health News:Mindray Announces Second Quarter 2009 Financial Results 4Health News:Mindray Announces Second Quarter 2009 Financial Results 5
... Knee System has been ... refined with the aid ... and manufacturing technology. Its ... stability, function, performance and ...
... Iso-C3D C-Arm imaging system interface sets a ... C-arm imaging. Combining mobility and accurate ... cooperative technologies deliver the most complete perspective ... is the new standard in the OR. ...
... mobile imaging just got better with ... instrumentation. Now using,your C-arm you can ... Add Visualization and Navigation Technology, ... Decision Making, Provide a Platform ...
... Asteion Multi puts the most advanced ... types of institutions, because it offers many ... Aquilion, but in a value-oriented platform. Asteion ... the high-throughput of multi-slice scanning, while also ...
Medicine Products: